Thermo Fisher Scientific Oncomine Myeloid Assay Gx
Thermo Fisher Scientific has announced a new portfolio of research-use-only hematology-oncology assays for its Ion Torrent Genexus System, with the firm's Oncomine Myeloid Assay GX being launched as the initial assay in the series.
The new panel allows simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day. It also provides the ability to profile 40 DNA targets and 29 fusion driver genes, allowing users to detect more than 600 fusion isotypes to identify biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia (AML), and myelodysplastic syndrome. The firm said that the assay maximizes detection of relevant biomarkers, including TP53, CEBPA, NPM1, RUNX1, PML-RARA, IDH 1, IDH 2, and FLT3-ITD, which is a common driver mutation associated with poor prognosis in AML.
Thermo Fisher intends to follow up the Myeloid Assay GX with additional hematology-oncology clinical research assays for B-cell and T-cell clonality and somatic hypermutation assessment through immune repertoire sequencing to study lymphoid malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, multiple myeloma, as well as Hodgkin's and non-Hodgkin's lymphomas. The firm also plans to launch a lymphoid gene panel covering a comprehensive set of targets relevant for a range of lymphoid neoplasms. All assays will be available for the Genexus System.
Qiagen SARS-CoV-2 Primer Panel for NGS
Qiagen has launched the QiaSeq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome. The panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to study the epidemiology of virus outbreaks. The two-step process applies QiaSeq technologies to conduct reverse transcription and cDNA synthesis from viral RNA samples, followed by generation of libraries compatible with Illumina sequencers. The workflow is faster and has lower input requirements than hybrid captures solutions, Qiagen said. The panel is supported with software pipelines tailored to SARS-CoV-2 genome analysis using Qiagen's CLC Genomics Workbench.
Bio-Techne, Leica Biosystems Automated RNA-ISH Probes for COVID-19 Research
Bio-Techne and Leica Biosystems have automated Bio-Techne's RNAscope COVID-19 probes on Bond RX, Leica's staining platform, for research use only. Researchers can now automate their COVID-19 research protocols, reducing manual labor and turnaround time, Bio-Techne said. Bond RX is a flexible, open platform with the capability to run Bio-Techne RNAscope duplex and multiplex protocols.
For more new products and services, please visit the New Products page on our website.